The DOI matches its Crossref record; 325 of the 325 references it cites were found in a registry or an index.
The Role of Oxidative Stress in Parkinson’s Disease
Open accessAbstract
Parkinson’s disease (PD) is caused by progressive neurodegeneration of dopaminergic (DAergic) neurons with abnormal accumulation of α-synuclein in substantia nigra (SN). Studies have suggested the potential involvement of dopamine, iron, calcium, mitochondria and neuroinflammation in contributing to overwhelmed oxidative stress and neurodegeneration in PD. Function studies on PD-causative mutations of SNCA, PRKN, PINK1, DJ-1, LRRK2, FBXO7 and ATP13A2 further indicate the role of oxidative stress in the pathogenesis of PD. Therefore, it is reasonable that molecules involved in oxidative stress, such as DJ-1, coenzyme Q10, uric acid, 8-hydroxy-2’-deoxyguanosin, homocysteine, retinoic acid/carotenes, vitamin E, glutathione peroxidase, superoxide dismutase, xanthine oxidase and products of lipid peroxidation, could be candidate biomarkers for PD. Applications of antioxidants to modulate oxidative stress could be a strategy in treating PD. Although a number of antioxidants, such as creatine, vitamin E, coenzyme Q10, pioglitazone, melatonin and desferrioxamine, have been tested in clinical trials, none of them have demonstrated conclusive evidence to ameliorate the neurodegeneration in PD patients. Difficulties in clinical studies may be caused by the long-standing progression of neurodegeneration, lack of biomarkers for premotor stage of PD and inadequate drug delivery across blood–brain barrier. Solutions for these challenges will be warranted for future studies with novel antioxidative treatment in PD patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–325 of 325
Grünewald, A., Arns, B., Seibler, P., Raković, A., Münchau, A. M., Ramírez, A., Sue, C. M., & Klein, C. (2012) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2011.12.035 · Cited by 137
Liu, C., Huang, Y. S., Hosokawa, M., Miyashita, K., & Hu, M. (2009) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2009.08.017 · Cited by 137
Impact of Dopamine Oxidation on Dopaminergic Neurodegeneration
Zhang, S., Wang, R., & Wang, G. (2018) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.8b00454 · Cited by 137
Melatonin protects against rotenone‐induced oxidative stress in a hemiparkinsonian rat model
Saravanan, K. S., Madathil, S. K., & Mohanakumar, K. P. (2006) · Journal of Pineal Research · doi:10.1111/j.1600-079x.2006.00412.x · Cited by 136
Increased oxidative damage in peripheral blood correlates with severity of Parkinson's disease
Chen, C., Liu, J., Wu, Y., Chen, Y., Cheng, H., Cheng, M., & Chiu, D. (2008) · Neurobiology of Disease · doi:10.1016/j.nbd.2008.11.011 · Cited by 136
Self-citationIravani, M. M., Leung, C. C. M., Sadeghian, M., Haddon, C. O., Rose, S., & Jenner, P. G. (2005) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2005.04220.x · Cited by 135
Wang, Y., Xu, H., Fu, Q., Ma, R., & Xiang, J. (2011) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2011.02.025 · Cited by 134
Kostrzewa, R. M. (2014) · Springer eBooks · doi:10.1007/978-1-4614-5836-4 · Cited by 134
LRRK2 enhances oxidative stress-induced neurotoxicity via its kinase activity
Heo, H. Y., Park, J.-M., Kim, C.-H., Han, B., Kim, K., & Seol, W. (2009) · Experimental Cell Research · doi:10.1016/j.yexcr.2009.09.014 · Cited by 133
McNaught, K. S. P., & Jenner, P. G. (1999) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1999.0732469.x · Cited by 132
Hass, C. J., Collins, M. A., & Juncos, J. L. (2007) · Neurorehabilitation and neural repair · doi:10.1177/1545968306293449 · Cited by 131
de Farias, C. C., Maes, M. H. J., Bonifácio, K. L., Bortolasci, C. C., Souza-Nogueira, A., Brinholi, F. F., Matsumoto, A. K., do Nascimento, M. A., de Melo, L. B., Nixdorf, S. L., et al. (2016) · Neuroscience Letters · doi:10.1016/j.neulet.2016.02.011 · Cited by 130
Thomas, M. P., Chartrand, K., Reynolds, A. D., Vitvitsky, V., Banerjee, R. V., & Gendelman, H. E. (2006) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.04315.x · Cited by 127
DJ-1 knock-down in astrocytes impairs astrocyte-mediated neuroprotection against rotenone
Mullett, S. J., & Hinkle, D. A. (2008) · Neurobiology of Disease · doi:10.1016/j.nbd.2008.09.013 · Cited by 127
Mochizuki, H., Choong, C., & Baba, K. (2020) · Journal of Neural Transmission · doi:10.1007/s00702-020-02149-3 · Cited by 127
Paterna, J., Leng, A., Weber, E., Feldon, J., & Büeler, H. (2007) · Molecular Therapy · doi:10.1038/sj.mt.6300067 · Cited by 126
Creatine as a booster for human brain function. How might it work?
Rae, C. D., & Bröer, S. (2015) · Neurochemistry International · doi:10.1016/j.neuint.2015.08.010 · Cited by 123
Disrupted and transgenic urate oxidase alter urate and dopaminergic neurodegeneration
Chen, X. M., Burdett, T. C., Desjardins, C. A., Logan, R. A., Cipriani, S., Xu, Y., & Schwarzschild, M. A. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1217296110 · Cited by 123
Isobe, C., Murata, T., Sato, C., et al. (2005) · Life Sciences · doi:10.1016/j.lfs.2005.02.014 · Cited by 122
Jiang, G., Hu, Y., Liu, L., Cai, J., Peng, C., & Li, Q. (2014) · Neurochemistry International · doi:10.1016/j.neuint.2014.06.003 · Cited by 122
DJ-1 isoforms in whole blood as potential biomarkers of Parkinson disease
Lin, X., Cook, T. J., Zabetian, C. P., Leverenz, J. B., Peskind, E. R., Hu, S., Cain, K. C., Pan, C., Edgar, J. S., Goodlett, D. R., et al. (2012) · Scientific Reports · doi:10.1038/srep00954 · Cited by 121
Nagatsu, T., & Nagatsu, I. (2016) · Journal of Neural Transmission · doi:10.1007/s00702-016-1596-4 · Cited by 118
Haleagrahara, N., Siew, C. J., Mitra, N. K., & Kumari, M. (2011) · Neuroscience Letters · doi:10.1016/j.neulet.2011.06.021 · Cited by 116
Shults, C. W., Beal, M. F., Fontaine, D., Nakano, K., & Haas, R. (1998) · Neurology · doi:10.1212/wnl.50.3.793 · Cited by 116
Homocysteine Metabolism, Atherosclerosis, and Diseases of Aging
McCully, K. S. (2015) · Comprehensive physiology · doi:10.1002/cphy.c150021 · Cited by 115
Plasma levels of DJ-1 as a possible marker for progression of sporadic Parkinson's disease
Waragai, M., Nakai, M., Wei, J., Fujita, M., Mizuno, H., Ho, G. J., Masliah, E., Akatsu, H., Yokochi, F., & Hashimoto, M. (2007) · Neuroscience Letters · doi:10.1016/j.neulet.2007.08.010 · Cited by 114
Thomas, B., & Mohanakumar, K. P. (2003) · Journal of Pineal Research · doi:10.1046/j.1600-079x.2003.00096.x · Cited by 114
Sziráki, I., Mohanakumar, K. P., Rauhala, P. V., Kim, H. G., YEH, K., & Chiueh, C. C. (1998) · Neuroscience · doi:10.1016/s0306-4522(97)00660-x · Cited by 113
Systemic Activation of Nrf2 Pathway in Parkinson's Disease
Petrillo, S., Schirinzi, T., Lazzaro, G. D., D’Amico, J., Colona, V. L., Bertini, E., Pierantozzi, M., Mari, L., Mercuri, N. B., Piemonte, F., et al. (2019) · Movement Disorders · doi:10.1002/mds.27878 · Cited by 113
Increased sensitivity to MPTP in human α-synuclein A30P transgenic mice
Nieto, M., Gil-Bea, F. J., Dalfó, E., Cuadrado‐Tejedor, M., Cabodevilla, F., Sánchez, B., Catena, S., Sesma, T., Ribé, E. M., Ferrer, I., et al. (2005) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2005.04.010 · Cited by 112
Gong, L., Zhang, Q., Zhang, N., Hua, W., Huang, Y., Di, P., Huang, T., Xu, X., Liu, C., Hu, L., et al. (2012) · Journal of Neurochemistry · doi:10.1111/jnc.12038 · Cited by 107
Mitochondrial dysfunction and Parkinson disease: a Parkin–AMPK alliance in neuroprotection
Hang, L., Thundyil, J., & Lim, K. (2015) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12820 · Cited by 106
Phase IIb Study of Intranasal Glutathione in Parkinson’s Disease
Mischley, L. K., Lau, R. C., Shankland, E. G., Wilbur, T. K., & Padowski, J. M. (2017) · Journal of Parkinson s Disease · doi:10.3233/jpd-161040 · Cited by 106
Hassanzadeh, K., & Rahimmi, A. (2018) · Journal of Cellular Physiology · doi:10.1002/jcp.26865 · Cited by 106
Erythrocyte antioxidant enzymes in Parkinson's disease.
Abraham, S., Soundararajan, C. C., Vivekanandhan, S., & Behari, M. (2005) · PubMed · Cited by 104
Mitochondrial stress management: a dynamic journey
Valera‐Alberni, M., & Cantó, C. (2018) · Cell Stress · doi:10.15698/cst2018.10.158 · Cited by 103
A lipid switch unlocks Parkinson’s disease-associated ATP13A2
Holemans, T., Sørensen, D. M., van Veen, S., Martin, S., Hermans, D., Kemmer, G. C., den Haute, C. V., Baekelandt, V., Pomorski, T. G., Agostinis, P., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1508220112 · Cited by 101
Yoritaka, A., Kawajiri, S., Yamamoto, Y., Nakahara, T., Ando, M., Hashimoto, K., Nagase, M., Saito, Y., & Hattori, N. (2015) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2015.05.022 · Cited by 100
Nakaso, K., Nakamura, C., Sato, H., Imamura, K., Takeshima, T., & Nakashima, K. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.11.095 · Cited by 99
F-box protein 7 mutations promote protein aggregation in mitochondria and inhibit mitophagy
Zhou, Z., Xie, S. P., Sathiyamoorthy, S., Saw, W. T., Sing, T. Y., Ng, S. H., Chua, H. P. H., Tang, A. M. Y., Shaffra, F., Zeng, L., et al. (2015) · Human Molecular Genetics · doi:10.1093/hmg/ddv340 · Cited by 99
No evidence for systemic oxidant stress in Parkinson's or Alzheimer's disease
Ahlskog, J. E., Uitti, R. J., Low, P. A., Tyce, G. M., Nickander, K. K., Petersen, R. C., & Kokmen, E. (1995) · Movement Disorders · doi:10.1002/mds.870100507 · Cited by 97
Perspectives on MAO-B in Aging and Neurological Disease: Where Do We Go From Here?
Kumar, M. J., & Andersen, J. K. (2004) · Molecular Neurobiology · doi:10.1385/mn:30:1:077 · Cited by 96
Ben‐Shachar, D., Eshel, G., Riederer, P. F., & Youdim, M. B. H. (1992) · Annals of Neurology · doi:10.1002/ana.410320718 · Cited by 95
Secretion of DJ-1 into the serum of patients with Parkinson's disease
Maita, C., Tsuji, S., Yabe, I., Hamada, S., Ogata, A., Maita, H., Iguchi‐Ariga, S. M. M., Sasaki, H., & Ariga, H. (2007) · Neuroscience Letters · doi:10.1016/j.neulet.2007.11.027 · Cited by 94
Altered redox state of platelet coenzyme Q 10 in Parkinson's disease
Götz, M. E., Gerstner, A., Harth, R., Dirr, A., Janetzky, B., Kuhn, W., Riederer, P., & Gerlach, M. (2000) · Journal of Neural Transmission · doi:10.1007/s007020050003 · Cited by 93
Katsuki, H., Kurimoto, E., Takemori, S., Kurauchi, Y., Hisatsune, A., Isohama, Y., Izumi, Y., Kume, T., Shudo, K., & Akaike, A. (2009) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2009.06171.x · Cited by 93
CSF levels of DJ-1 and tau distinguish MSA patients from PD patients and controls
Herbert, M. K., Eeftens, J. M., Aerts, M. B., Esselink, R. A. J., Bloem, B. R., Kuiperij, H. B., & Verbeek, M. M. (2013) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2013.09.003 · Cited by 92
Baicalein attenuates 6-hydroxydopamine-induced neurotoxicity in SH-SY5Y cells
Lee, H. J., Noh, Y. H., Lee, D., Kim, Y. S., Kim, K. Y., Chung, Y. H., Lee, W. B., & Kim, S. S. (2005) · European Journal of Cell Biology · doi:10.1016/j.ejcb.2005.07.003 · Cited by 92
Tan, M., Yoshida, K. J., Zhao, P., Zhang, L., Nolin, T. D., Piquette‐Miller, M., Galetin, A., & Huang, S. M. (2017) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.807 · Cited by 92
Barbiero, J. K., Santiago, R. M., Persike, D. S., Fernandes, M. J. D. S., Tonin, F. S., Cunha, C. D., Boschen, S. L., Lima, M. M. S., & Vital, M. A. B. F. (2014) · Behavioural Brain Research · doi:10.1016/j.bbr.2014.08.014 · Cited by 91
Neuroprotection of Coenzyme Q10 in Neurodegenerative Diseases
Yang, X., Zhang, Y., Xu, H., Luo, X., Yu, J. J., Liu, J., & Chuen-Chung, R. (2015) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026615666150827095252 · Cited by 90
Armstrong, J. S., Whiteman, M., Rose, P. E., & Jones, D. P. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m307841200 · Cited by 89
Zhang, H., Jia, H., Liu, J., Ao, N., Yan, B., Shen, W., Wang, X., Li, X., Luo, C. Y., & Liu, J. (2008) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2008.00390.x · Cited by 89
Huang, B., Liu, J., Ju, C., Yang, D., Chen, G., Xu, S. S., Zeng, Y., Yan, X., Wang, W., Liu, D., et al. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18102043 · Cited by 88
The Structure and Function of the Dopamine Transporter and its Role in CNS Diseases
McHugh, P., & Buckley, D. A. (2015) · Vitamins and hormones · doi:10.1016/bs.vh.2014.12.009 · Cited by 87
Saito, Y., Hamakubo, T., Yoshida, Y., Ogawa, Y., Hara, Y., Fujimura, H., Imai, Y., Iwanari, H., Mochizuki, Y., Shichiri, M., et al. (2009) · Neuroscience Letters · doi:10.1016/j.neulet.2009.08.074 · Cited by 87
Interactions between Calcium and Alpha-Synuclein in Neurodegeneration
Rcom-H'cheo-Gauthier, A. N., Goodwin, J., & Pountney, D. L. (2014) · Biomolecules · doi:10.3390/biom4030795 · Cited by 86
Sensitization of Neuronal Cells to Oxidative Stress with Mutated Human α‐Synuclein
Ko, L., Mehta, N. D., Farrer, M. J., Easson, C., Hussey, J., Yen, S. H., Hardy, J., & Yen, S.-H. C. (2000) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2000.0752546.x · Cited by 86
Li, X.-X., He, G., Mu, X. L., Xu, B., Tian, S., Yu, X., Meng, F.-R., Xuan, Z.-H., & Du, G. (2011) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2011.09.181 · Cited by 85
8-OHdG in Cerebrospinal Fluid as a Marker of Oxidative Stress in Various Neurodegenerative Diseases
Gmitterová, K., Heinemann, U., Gawinecka, J., Varges, D., Ciesielczyk, B., Valkovič, P., Benetin, J., & Zerr, I. (2009) · Neurodegenerative Diseases · doi:10.1159/000237221 · Cited by 85
Lou, H., Xu, J., Ren, D., Wei, X., & Zhang, X. (2012) · Neurochemistry International · doi:10.1016/j.neuint.2012.05.013 · Cited by 82
Genetics of Huntington disease
Nance, M. (2017) · Handbook of clinical neurology · doi:10.1016/b978-0-12-801893-4.00001-8 · Cited by 82
DJ-1 Expression Modulates Astrocyte-Mediated Protection Against Neuronal Oxidative Stress
Mullett, S. J., Maio, R. D., Greenamyre, J. T., & Hinkle, D. A. (2012) · Journal of Molecular Neuroscience · doi:10.1007/s12031-012-9904-4 · Cited by 73
Formulation of tocopherol nanocarriers and in vitro delivery into human skin
Abla, M. J., & Banga, A. K. (2014) · International Journal of Cosmetic Science · doi:10.1111/ics.12119 · Cited by 72
Evidence for More than One Parkinson's Disease-Associated Variant within the HLA Region
Hill‐Burns, E. M., Factor, S. A., Zabetian, C. P., Thomson, G. J., & Payami, H. (2011) · PLoS ONE · doi:10.1371/journal.pone.0027109 · Cited by 71
Geed, M., Garabadu, D., Ahmad, A., & Krishnamurthy, S. (2013) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2013.12.008 · Cited by 71
Xiao, H., Lv, F., Xu, W., Zhang, L., Jing, P., & Cao, X. (2011) · Toxicology · doi:10.1016/j.tox.2011.10.007 · Cited by 70
Plasma F2A Isoprostane Levels in Alzheimer’s and Parkinson’s Disease
Irizarry, M. C., Yao, Y., Hyman, B. T., Growdon, J. H., & Praticò, D. (2007) · Neurodegenerative Diseases · doi:10.1159/000107699 · Cited by 68
Plasma levels of lipid peroxides in patients with Parkinson's disease.
Sanyal, J., Bandyopadhyay, S. K., Banerjee, T. K., Mukherjee, S. C., Chakraborty, D. P., Ray, B. C., & Rao, V. R. (2009) · PubMed · Cited by 68
Uhl, G. R., Li, S., Takahashi, N., Itokawa, K., Lin, Z., Hazama, M., & Sora, I. (2000) · The FASEB Journal · doi:10.1096/fj.00-0205rev · Cited by 66
Nuclear translocation of DJ-1 during oxidative stress-induced neuronal cell death
Kim, S., Park, Y.-J., Hwang, I.-Y., Youdim, M. B. H., Park, K., & Oh, Y. J. (2012) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2012.05.035 · Cited by 66
Cipriani, S., Desjardins, C. A., Burdett, T. C., Xu, Y., Xu, K., & Schwarzschild, M. A. (2012) · PLoS ONE · doi:10.1371/journal.pone.0037331 · Cited by 66
Effects of pioglitazone and retinoic acid in a rotenone model of Parkinson's disease
Ulusoy, K. G., Çelik, T., Kayır, H., Gürsoy, M., Işık, A. T., & Uzbay, T. I. (2011) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2011.05.001 · Cited by 65
Çokal, B. G., Yurtdaş, M., Güler, S. K., Güneş, H. N., Uçar, C. A., Aytaç, B., Durak, İ., Yoldaş, T. K., Durak, İ., & Çubukçu, H. C. (2016) · Neurological Sciences · doi:10.1007/s10072-016-2782-8 · Cited by 65
HWANG, Y., Kim, H., Han, E. H., et al. (2008) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2008.04.019 · Cited by 64
Selected Contribution: Lung hypoxia: antioxidant and antiapoptotic effects of liposomal α-tocopherol
Minko, T., Stefanov, A., & Pozharov, V. P. (2002) · Journal of Applied Physiology · doi:10.1152/japplphysiol.00007.2002 · Cited by 64
Vitamins and entacapone in levodopa-induced hyperhomocysteinemia: A randomized controlled study
Postuma, R. B., Espay, A. J., Zadikoff, C., Suchowersky, O., Martin, W. R. W., Lafontaine, A. L., Ranawaya, R., Camicioli, R. M., & Lang, A. E. (2006) · Neurology · doi:10.1212/01.wnl.0000219815.83681.f7 · Cited by 64
Plasma oxidative and inflammatory markers in patients with idiopathic Parkinson’s disease
Andican, G., Konukoğlu, D., Bozluolçay, M., Bayülkem, K., Firtiına, S., & Burçak, G. (2012) · Acta Neurologica Belgica · doi:10.1007/s13760-012-0015-3 · Cited by 63
Tieu, K., Zuo, D., & Yu, P. H. (1999) · Journal of Neuroscience Research · Cited by 63
Fang, Y., He, X., & Wang, D. (2013) · Neurochemical Research · doi:10.1007/s11064-013-1079-z · Cited by 62
Protective Effect of Oral Hesperetin Against Unilateral Striatal 6-Hydroxydopamine Damage in the Rat
Kiasalari, Z., Khalili, M., Baluchnejadmojarad, T., & Roghani, M. (2015) · Neurochemical Research · doi:10.1007/s11064-015-1796-6 · Cited by 62
Kim, J. H., Hwang, J., Shim, E., Chung, E.-J., Jang, S. H., & Koh, S. (2017) · Nutrition Research and Practice · doi:10.4162/nrp.2017.11.2.114 · Cited by 62
Vitamin E nanoemulsions characterization and analysis
Diane, J. M. M., & Burgess, J. R. (2014) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2014.02.034 · Cited by 61
Wang, Y., Yu, H., Pu, X., & Du, G. (2013) · Molecules · doi:10.3390/molecules181214726 · Cited by 61
FBXO7 mutations in Parkinson's disease and multiple system atrophy
Conedera, S., Apaydın, H., Li, Y., Yoshino, H., Ikeda, A., Matsushima, T., Funayama, M., Nishioka, K., & Hattori, N. (2016) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2016.01.003 · Cited by 61
CART Peptide Is a Potential Endogenous Antioxidant and Preferentially Localized in Mitochondria
Mao, P., Meshul, C. K., Thuillier, P., Goldberg, N. R. S., & Reddy, P. H. (2012) · PLoS ONE · doi:10.1371/journal.pone.0029343 · Cited by 60
Dewapriya, P., Himaya, S. W. A., Li, Y.-X., & Kim, S. (2013) · Food Chemistry · doi:10.1016/j.foodchem.2013.04.004 · Cited by 60
Masters, J. M., Noyce, A. J., Warner, T. T., Giovannoni, G., & Proctor, G. (2015) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2015.07.021 · Cited by 58
Wang, P., Niu, L., Gao, L., Li, W.-X., Jia, D., Wang, X.-L., & Gao, G.-D. (2010) · Journal of International Medical Research · doi:10.1177/147323001003800336 · Cited by 55
Wang, Q., Xu, Y., Liu, S., & Ma, Z. (2017) · Oncotarget · doi:10.18632/oncotarget.17618 · Cited by 55
Sharma, A. I., Kaur, P., Kumar, B., Prabhakar, S. K., & Gill, K. D. (2007) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2007.06.009 · Cited by 53
Serum antioxidant enzyme activity in Parkinson's disease
Kalra, J., Rajput, A. H., Mantha, S. V., et al. (1992) · Molecular and Cellular Biochemistry · doi:10.1007/bf02454194 · Cited by 53
Iravani, M. M., Sadeghian, M., Leung, C. C. M., Jenner, P. G., & Rose, S. (2012) · Neuroscience Letters · doi:10.1016/j.neulet.2012.01.022 · Cited by 53
Serum levels of alpha‐tocopherol (vitamin E) in Parkinson's disease
Fernández–Calle, P., Molina, J. A., Jiménez-Jiménez, F. J., Vázquez, A., Pondal, M., Ruiz, P., Urra, D. G., Domingo, J. V., & Codoceo, R. (1992) · Neurology · doi:10.1212/wnl.42.5.1064 · Cited by 51
VITAMINS AND ENTACAPONE IN LEVODOPA-INDUCED HYPERHOMOCYSTEINEMIA: A RANDOMIZED CONTROLLED STUDY
Rocco, A. D., & Werner, P. (2007) · Neurology · doi:10.1212/01.wnl.0000265412.38632.96 · Cited by 50
Lu, X.-L., Yao, X.-L., Liu, Z., Zhang, H., Li, W., Li, Z., Wang, G., Pang, J., Lin, Y., Xu, Z., et al. (2010) · Brain Research · doi:10.1016/j.brainres.2010.03.071 · Cited by 49
Protection of dopaminergic cells by urate requires its accumulation in astrocytes
Cipriani, S., Desjardins, C. A., Burdett, T. C., Xu, Y., Xu, K., & Schwarzschild, M. A. (2012) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2012.07820.x · Cited by 48
Rosmarinic Acid Inhibits 6-OHDA-induced Neurotoxicity by Anti-oxidation in MES23.5 Cells
Ren, P., Jiang, H. F., Li, R., Wang, J., Song, N., Xu, H., & Xie, J. (2009) · Journal of Molecular Neuroscience · doi:10.1007/s12031-009-9182-y · Cited by 48
Perfeito, R., Ribeiro, M., & Rego, A. C. (2016) · Archives of Toxicology · doi:10.1007/s00204-016-1788-6 · Cited by 48
Kim, H. G., Ju, M. S., Kim, D., Hong, J., Cho, S., Cho, K., Park, W., Lee, E. H., Kim, S. Y., & Oh, M. S. (2010) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/j.1742-7843.2010.00612.x · Cited by 46
Covy, J. P., Waxman, E. A., & Giasson, B. I. (2012) · Journal of Neuroscience Research · doi:10.1002/jnr.23112 · Cited by 46
LI, D.-W., Guang-ren, L., Lu, Y., Liu, Z., Chang, M., YAO, M., CHENG, W., & Hu, L. (2013) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2013.1361 · Cited by 44
Abdin, A. A., & Sarhan, N. (2011) · Neuroscience Research · doi:10.1016/j.neures.2011.08.008 · Cited by 43
Mechanistic contributions of FBXO7 to Parkinson disease
Joseph, S., Schulz, J. B., & Stegmüller, J. (2017) · Journal of Neurochemistry · doi:10.1111/jnc.14253 · Cited by 39
Hirayama, M., Nakamura, T., Watanabe, H., Uchida, K., Hama, T., Hara, T., Niimi, Y., Ito, M., Ohno, K., & Sobue, G. (2010) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2010.11.004 · Cited by 38
α-Synuclein and DJ-1 as Potential Biological Fluid Biomarkers for Parkinson’s Disease
Waragai, M., Sekiyama, K., Sekigawa, A., Takamatsu, Y., Fujita, M., & Hashimoto, M. (2010) · International Journal of Molecular Sciences · doi:10.3390/ijms11114257 · Cited by 38
Chang, K., Lee‐Chen, G., Wu, Y., Chen, Y.-J., Lin, J.-L., Li, M. C., Chen, I., Lo, Y., Wu, H.-C., & Chen, C. (2016) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2016.01.001 · Cited by 38
Self-citationLinking F-box protein 7 and parkin to neuronal degeneration in Parkinson’s disease (PD)
Zhou, Z., Sathiyamoorthy, S., Angeles, D. C., & Tan, E. K. (2016) · Molecular Brain · doi:10.1186/s13041-016-0218-2 · Cited by 38
The Effect of Coenzyme Q10 Therapy in Parkinson Disease Could Be Symptomatic
Horstink, M. W. I. M., & van Engelen, B. G. M. (2003) · Archives of Neurology · doi:10.1001/archneur.60.8.1170-b · Cited by 36
Systemic Activation of Nrf2 Pathway in Parkinson's Disease
Petrillo, S., Schirinzi, T., Lazzaro, G. D., D’Amico, J., Colona, V. L., Bertini, E., Pierantozzi, M., Mari, L., Mercuri, N. B., Piemonte, F., et al. (2019) · Zenodo (CERN European Organization for Nuclear Research) · doi:10.5281/zenodo.4585633 · Cited by 35
Oxidized DJ-1 Levels in Urine Samples as a Putative Biomarker for Parkinson’s Disease
Jang, J., Jeong, S., Lee, S. I., Seol, W., Seo, H., Son, I., & Ho, D. H. (2018) · Parkinson s Disease · doi:10.1155/2018/1241757 · Cited by 34
Pioglitazone use and Parkinson’s disease: a retrospective cohort study in Taiwan
Wu, H.-F., Kao, L., Shih, J., Kao, H., Chou, Y., Li, I., & Kao, S. (2018) · BMJ Open · doi:10.1136/bmjopen-2018-023302 · Cited by 32
Serum lipid peroxides in patients with Parkinson's disease
Molina, J., Jiménez‐Jiménez, F. J., Fernández–Calle, P., Lalinde, L., Tenías, J. M., Pondal, M., Vázquez, A., & Codoceo, R. (1992) · Neuroscience Letters · doi:10.1016/0304-3940(92)90033-4 · Cited by 31
Bhattacharjee, N., Paul, R. K., Giri, A., & Borah, A. (2016) · Biochemistry and Biophysics Reports · doi:10.1016/j.bbrep.2016.02.013 · Cited by 31
Mechanisms of Dopamine Oxidation and Parkinson’s Disease
Segura‐Aguilar, J., & Paris, I. B. (2014) · Springer eBooks · doi:10.1007/978-1-4614-5836-4_16 · Cited by 30
Plasma levels of vitamin E in Parkinson's disease
Nicoletti, G., Crescibene, L., Scornaienchi, M., Bastone, L., Bagalà, A., Napoli, I., Caracciolo, M., & Quattrone, A. (2001) · Archives of Gerontology and Geriatrics · doi:10.1016/s0167-4943(01)00092-9 · Cited by 30
Braidy, N., Gai, W.-P., Xu, Y. H., Sachdev, P. S., Guillemin, G. J., Jiang, X., Ballard, J. W. O., Horan, M. P., Fang, Z. M., Chong, B. H., et al. (2013) · Neurotoxicity Research · doi:10.1007/s12640-013-9420-5 · Cited by 28
Stimulation of vesicular monoamine transporter 2 activity by DJ-1 in SH-SY5Y cells
Ishikawa, S., Tanaka, Y., Takahashi-Niki, K., Niki, T., Ariga, H., & Iguchi‐Ariga, S. M. M. (2012) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2012.04.095 · Cited by 26
Wei, P., Lee‐Chen, G., Chen, C., Wu, Y., Chen, Y.-J., Lin, J.-L., Lo, Y., Yao, C., & Chang, K. (2019) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2019/5074367 · Cited by 26
Self-citationChen, C., Lin, C., Wu, Y., Yen, C.-Y., Huang, Y., Lin, J.-L., Lin, C., Chen, W.-L., Chao, C., Lee‐Chen, G., et al. (2020) · Cells · doi:10.3390/cells9051230 · Cited by 23
Self-citationLuk, B., Mohammed, M., Liu, F., & Lee, F. J. S. (2015) · PLoS ONE · doi:10.1371/journal.pone.0136641 · Cited by 22
Wood‐Kaczmar, A., Gandhi, S., Yao, Z., Abramov, A. Y., Miljan, E., Keen, G., Stanyer, L., Hargreaves, I. P., Klupsch, K., Deas, E., et al. (2008) · PLoS ONE · doi:10.1371/annotation/17d5aaa1-c6d8-4aad-a9a4-56b2c1220c83 · Cited by 17
Piltonen, M., Savolainen, M. H., Patrikainen, S., Baekelandt, V., Myöhänen, T. T., & Männistö, P. T. (2012) · Neuroscience · doi:10.1016/j.neuroscience.2012.11.045 · Cited by 16
The strategic function of the P5-ATPase ATP13A2 in toxic waste disposal
Pinto, F. D. T., & Adamo, H. P. (2017) · Neurochemistry International · doi:10.1016/j.neuint.2017.11.008 · Cited by 12
Association of genetic variants within HLA-DR region with Parkinson's disease in Taiwan
Chang, K., Wu, Y., Chen, Y., Fung, H., & Chen, C. (2019) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2019.11.002 · Cited by 8
Self-citation
Cited by
González, P., Lozano, P., Ros, G., & Solano, F. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24119352 · Cited by 777
Role of Coenzyme Q10 in Health and Disease: An Update on the Last 10 Years (2010–2020)
Cirilli, I., Damiani, E., Dludla, P. V., Hargreaves, I., Marcheggiani, F., Millichap, L. E., Orlando, P., Silvestri, S., & Tiano, L. (2021) · Antioxidants · doi:10.3390/antiox10081325 · Cited by 115
Reflections of an aging free radical
Halliwell, B. (2020) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2020.10.010 · Cited by 75
Pentón-Rol, G., Marín-Prida, J., & McCarty, M. F. (2021) · Current Neuropharmacology · doi:10.2174/1570159x19666210408123807 · Cited by 73
Psychotropic medication use and Parkinson's disease risk amongst older women
Beydoun, H. A., Saquib, N., Wallace, R. B., Chen, J., Coday, M., Naughton, M. J., Beydoun, M. A., Shadyab, A. H., Zonderman, A. B., & Brunner, R. L. (2022) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.51614 · Cited by 12
Metadata
- Authors
- Chang, K.-H., & Chen, C.-M.
- Venue
- Antioxidants
- Publisher
- MDPI AG
- Published
- 2020-07-08
- Volume
- 9
- Issue
- 7
- Pages
- 597
- ISSN
- 2076-3921 (ISSN-L)
- OpenAlex
- W3042059273
- Cited by
- 341
- References
- 325
- FWCI
- 12.24
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.